Synchrony Financial vs Zoetis Inc — how do they compare? Synchrony Financial trades at $72.23 (market cap $24.69B), while Zoetis Inc trades at $76.07 (market cap $31.95B). The key difference: Zoetis Inc is the larger of the two by market cap, and Zoetis Inc pays the higher dividend (2.78%). Which is the better fit depends on your goals.
| SYF | ZTS | |
|---|---|---|
Market Cap | $24.69B | $31.95B |
Sector | Financials | Health |
52-Week High | $88.47 | $156.76 |
52-Week Low | $63.78 | $71.91 |
Dividend Yield | 1.63% | 2.78% |
Enterprise Value | — | $39.24B |
Signals from Pluang's Aura AI — not financial advice
Synchrony Financial (SYF) trades at $73.41, down 0.29% with a bearish technical signal. The stock shows strong fundamentals with a P/E of 7.62, net income margin of 24.06%, and consistent earnings beats. Recent corporate actions include a $0.30 dividend payment in May 2026. Cash flow remains positive despite projected 2026 challenges. Technical indicators show mixed signals with RSI at neutral levels but bearish moving averages.
SYF presents value opportunity with attractive valuation metrics and strong profitability, though facing near-term technical headwinds. Key risks include economic sensitivity as a consumer lender and potential margin pressure from rising rates. Analyst consensus remains bullish with $86.38 price target representing 17.7% upside potential from current levels.
No Aura AI signal available yet.
Trailing returns across standard periods
Latest headlines on both assets
Synchrony Financial is a premier consumer financial services company and the largest provider of private-label credit cards in the United States. Spun off from GE Capital in 2014, it operates through a unique B2B2C model, embedding its financing products within the ecosystems of major partners like Amazon, Lowe’s, and PayPal. Synchrony leverages deep data analytics and a diverse multi-platform strategy—spanning retail, health, and auto—to drive customer loyalty and provide specialized credit solutions at the point of sale.
Read more on SYF →Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →